Fig. 4: NAb responses in immunized mice.
Experiment 1: (a) Live-virus microneutralization (micro-VNT50) titers against WT (Wuhan-Hu1) live-virus at two weeks after receiving each vaccine dose. b Pseudovirus neutralization test (psVNT50) titers at two weeks after the second dose againt WT (Wuhan-Hu1), Delta (B.1.617.2), Omciron (BA.1, and BA.4/5) variants. Experiment 2: c micro-VNT50 titers against WT (Wuhan-Hu1), Alpha (B.1.1.7), Beta (B.1.351), and Delta (B.1.617.2) live-virus at two weeks after receiving various homologous or heterologous prime/boost regimens. d psVNT50 NAb titer results at two weeks after the second dose in various prime/boost regimens againt Omicron BA.1 and BA.4/5 subvariants. Experiment 3: e psVNT50 NAb against WT (Wuhan-Hu1), Delta (B.1.617.2), and Omicron (BA.1 and BA.4/5) variants for NAb durability and effect of 3rd dose of ChulaCov19 studies. The titers were determined in duplicate assays from 5 mice in each group. Note; 4 mice in 10 µg group were analyzed for psVNT50 against BA.4/5 due to the limited volume of serum samples. Each dot represents an individual animal. Bars represent the GMTs and 95% CI for each group. Statistical significance was determined by two-sided Mann–Whitney tests. Differences were considered significant at p < 0.05 with exact p-values shown. p < 0.05 and p < 0.01 are indicated by * and **, respectively. Source data are provided as a Source Data file.
